JP2019507354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507354A5 JP2019507354A5 JP2018559674A JP2018559674A JP2019507354A5 JP 2019507354 A5 JP2019507354 A5 JP 2019507354A5 JP 2018559674 A JP2018559674 A JP 2018559674A JP 2018559674 A JP2018559674 A JP 2018559674A JP 2019507354 A5 JP2019507354 A5 JP 2019507354A5
- Authority
- JP
- Japan
- Prior art keywords
- history
- less
- biomarkers
- determining
- intervention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 57
- 208000010125 myocardial infarction Diseases 0.000 claims description 45
- 238000004393 prognosis Methods 0.000 claims description 34
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 31
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims description 31
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims description 25
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 25
- 102000016776 Midkine Human genes 0.000 claims description 22
- 108010092801 Midkine Proteins 0.000 claims description 22
- 208000029078 coronary artery disease Diseases 0.000 claims description 20
- 102000004264 Osteopontin Human genes 0.000 claims description 19
- 108010081689 Osteopontin Proteins 0.000 claims description 19
- 108010076365 Adiponectin Proteins 0.000 claims description 18
- 102000011690 Adiponectin Human genes 0.000 claims description 18
- 210000004556 brain Anatomy 0.000 claims description 17
- 230000000747 cardiac effect Effects 0.000 claims description 17
- 239000002934 diuretic Substances 0.000 claims description 17
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 17
- 230000001452 natriuretic effect Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 210000004351 coronary vessel Anatomy 0.000 claims description 16
- 238000003745 diagnosis Methods 0.000 claims description 14
- 230000000414 obstructive effect Effects 0.000 claims description 12
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims description 10
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims description 10
- 238000001631 haemodialysis Methods 0.000 claims description 10
- 230000000322 hemodialysis Effects 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 9
- 101710188053 Protein D Proteins 0.000 claims description 9
- 101710132893 Resolvase Proteins 0.000 claims description 9
- 239000003580 lung surfactant Substances 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- 102000007592 Apolipoproteins Human genes 0.000 claims description 8
- 108010071619 Apolipoproteins Proteins 0.000 claims description 8
- 238000002399 angioplasty Methods 0.000 claims description 8
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 8
- 102000004237 Decorin Human genes 0.000 claims description 7
- 108090000738 Decorin Proteins 0.000 claims description 7
- 102000004890 Interleukin-8 Human genes 0.000 claims description 7
- 108090001007 Interleukin-8 Proteins 0.000 claims description 7
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims description 7
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 7
- 102000036675 Myoglobin Human genes 0.000 claims description 7
- 108010062374 Myoglobin Proteins 0.000 claims description 7
- 238000007887 coronary angioplasty Methods 0.000 claims description 7
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 7
- 229940096397 interleukin-8 Drugs 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 5
- 102000011772 Apolipoprotein C-I Human genes 0.000 claims description 5
- 108010076807 Apolipoprotein C-I Proteins 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 229940066294 lung surfactant Drugs 0.000 claims description 4
- 230000005586 smoking cessation Effects 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 4
- -1 stem cell factor Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 238000010968 computed tomography angiography Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000009662 stress testing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021097387A JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2022150335A JP2022171936A (ja) | 2016-02-01 | 2022-09-21 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2024214563A JP2025029196A (ja) | 2016-02-01 | 2024-12-09 | 心臓血管疾患及び事象のための診断及び予後方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289513P | 2016-02-01 | 2016-02-01 | |
| US62/289,513 | 2016-02-01 | ||
| US201662378535P | 2016-08-23 | 2016-08-23 | |
| US62/378,535 | 2016-08-23 | ||
| PCT/US2017/016081 WO2017136464A1 (en) | 2016-02-01 | 2017-02-01 | Diagnostic and prognostic methods for cardiovascular diseases and events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021097387A Division JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507354A JP2019507354A (ja) | 2019-03-14 |
| JP2019507354A5 true JP2019507354A5 (enExample) | 2020-03-12 |
| JP7134870B2 JP7134870B2 (ja) | 2022-09-12 |
Family
ID=59500904
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559674A Active JP7134870B2 (ja) | 2016-02-01 | 2017-02-01 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2021097387A Active JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2022150335A Pending JP2022171936A (ja) | 2016-02-01 | 2022-09-21 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2024214563A Pending JP2025029196A (ja) | 2016-02-01 | 2024-12-09 | 心臓血管疾患及び事象のための診断及び予後方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021097387A Active JP7403498B2 (ja) | 2016-02-01 | 2021-06-10 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2022150335A Pending JP2022171936A (ja) | 2016-02-01 | 2022-09-21 | 心臓血管疾患及び事象のための診断及び予後方法 |
| JP2024214563A Pending JP2025029196A (ja) | 2016-02-01 | 2024-12-09 | 心臓血管疾患及び事象のための診断及び予後方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10983135B2 (enExample) |
| EP (2) | EP4574024A3 (enExample) |
| JP (4) | JP7134870B2 (enExample) |
| KR (1) | KR20180101595A (enExample) |
| CN (2) | CN108700596A (enExample) |
| AU (1) | AU2017214469A1 (enExample) |
| BR (1) | BR112018015698A2 (enExample) |
| CA (1) | CA3012192A1 (enExample) |
| MA (1) | MA43980A (enExample) |
| MX (1) | MX2018009304A (enExample) |
| RU (1) | RU2018130866A (enExample) |
| SG (1) | SG11201805906WA (enExample) |
| WO (1) | WO2017136464A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4574024A3 (en) | 2016-02-01 | 2025-10-08 | Prevencio, Inc. | Diagnostic and prognostic methods for cardiovascular diseases and events |
| JP7470268B2 (ja) * | 2017-09-14 | 2024-04-18 | ラボラトリー・コーポレイション・オブ・アメリカ・ホールディングス | 関節リウマチ患者における心筋梗塞および重篤な感染リスクを評価するためのバイオマーカおよび方法 |
| JP7372251B2 (ja) * | 2017-11-02 | 2023-10-31 | プリベンシオ，インコーポレイテッド | 末梢動脈疾患、大動脈弁狭窄症についての診断および予後の方法、ならびにアウトカム |
| US11009452B2 (en) | 2018-01-26 | 2021-05-18 | Viavi Solutions Inc. | Reduced false positive identification for spectroscopic quantification |
| WO2020169751A1 (en) * | 2019-02-20 | 2020-08-27 | Fundació Institut D'investigació En Ciènces De La Salut Germans Trias I Pujol | In vitro method for predicting mortality risk in patients suffering from shock |
| CN110232975A (zh) * | 2019-05-20 | 2019-09-13 | 郑州大学第一附属医院 | 一种对糖尿病肾病患者3年内进入到肾脏替代治疗风险预测的方法 |
| CN110491512A (zh) * | 2019-08-08 | 2019-11-22 | 郑州大学第一附属医院 | 一种对肾活检确诊糖尿病肾病患者3年内进入到终末期肾脏病风险预测的方法 |
| CN110596399B (zh) * | 2019-08-29 | 2022-07-22 | 首都医科大学附属北京安贞医院 | 检测血管生成素样蛋白8含量的物质的应用 |
| CN110970131B (zh) * | 2019-10-24 | 2024-01-26 | 中国医科大学附属盛京医院 | 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用 |
| RU2726314C1 (ru) * | 2019-11-15 | 2020-07-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ раннего прогнозирования риска острого повреждения почек у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования |
| RU2760445C1 (ru) * | 2020-11-13 | 2021-11-25 | Виталий Юрьевич Мишланов | Способ диагностики патологических состояний человека |
| WO2022202360A1 (ja) * | 2021-03-23 | 2022-09-29 | テルモ株式会社 | 情報処理装置、情報処理方法およびプログラム |
| CN113342963B (zh) * | 2021-04-29 | 2022-03-04 | 山东大学 | 一种基于迁移学习的服务推荐方法及系统 |
| RU2770550C1 (ru) * | 2021-05-31 | 2022-04-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования сердечно-сосудистого риска с помощью определения уровня эстрогенов |
| CA3246341A1 (en) * | 2022-03-30 | 2023-10-05 | Inflammatix, Inc. | DIAGNOSTIC METHODS FOR MYOCARDIAL INFARCTION |
| CN114974576A (zh) * | 2022-07-12 | 2022-08-30 | 曜立科技(北京)有限公司 | 一种基于元数据的心脑血管数疾病诊断管理系统 |
| CN115185936B (zh) | 2022-07-12 | 2023-02-03 | 曜立科技(北京)有限公司 | 一种基于大数据的医疗临床数据质量分析系统 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US20080202927A1 (en) | 2000-11-03 | 2008-08-28 | Clinical Micro Sensors, Inc. | Devices and methods for biochip multiplexing |
| US20030134433A1 (en) | 2002-01-16 | 2003-07-17 | Nanomix, Inc. | Electronic sensing of chemical and biological agents using functionalized nanostructures |
| US20060228723A1 (en) | 2002-01-16 | 2006-10-12 | Keith Bradley | System and method for electronic sensing of biomolecules |
| US9234867B2 (en) | 2003-05-16 | 2016-01-12 | Nanomix, Inc. | Electrochemical nanosensors for biomolecule detection |
| US8425745B2 (en) | 2006-10-06 | 2013-04-23 | Nanomix, Inc. | Electrochemical nanosensors for biomolecule detection |
| US8685711B2 (en) | 2004-09-28 | 2014-04-01 | Singulex, Inc. | Methods and compositions for highly sensitive detection of molecules |
| WO2006089226A1 (en) * | 2005-02-17 | 2006-08-24 | University Of Florida Research Foundation, Inc. | β-BLOCKER PHARMACOGENETICS IN HEART FAILURE |
| CN101495862A (zh) * | 2005-06-24 | 2009-07-29 | 利兰·斯坦福青年大学托管委员会 | 诊断和监测动脉粥样硬化性心血管疾病的方法和组合物 |
| US8093017B2 (en) * | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
| WO2007123708A2 (en) * | 2006-03-31 | 2007-11-01 | Epitome Biosystems, Inc. | Post translational modification pattern analysis |
| EP2924440A3 (en) * | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| DE112007003185A5 (de) | 2006-10-26 | 2009-10-01 | Brahms Aktiengesellschaft | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
| CA2697357A1 (en) | 2007-04-16 | 2008-10-30 | John T. Mcdevitt | Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics |
| US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
| US20100267062A1 (en) * | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
| US8241861B1 (en) * | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
| AU2010255354A1 (en) | 2009-06-04 | 2012-02-02 | Koninklijke Philips Electronics, N.V. | Method and system for providing behavioural therapy for insomnia |
| US8450069B2 (en) | 2009-06-08 | 2013-05-28 | Singulex, Inc. | Highly sensitive biomarker panels |
| US20120208715A1 (en) * | 2009-08-20 | 2012-08-16 | Mcdevitt John T | Methods and compositions for diagnosis of acute myocardial infarction (ami) |
| WO2011072177A2 (en) * | 2009-12-09 | 2011-06-16 | Aviir, Inc. | Biomarker assay for diagnosis and classification of cardiovascular disease |
| KR101256928B1 (ko) * | 2010-01-20 | 2013-04-19 | 주식회사디엔에이링크 | 비만 또는 당뇨에 관련된 단일염기다형성 및 그의 용도 |
| WO2012072595A1 (en) * | 2010-11-30 | 2012-06-07 | Universiteit Gent | Platelet factor 4 variant for the prognosis of cardiovascular outcome in patients having heart disease |
| US9547004B2 (en) | 2011-03-09 | 2017-01-17 | Abionic Sa | Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof |
| WO2012145037A1 (en) | 2011-04-19 | 2012-10-26 | Scott & White Healthcare | Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease |
| US20140011811A1 (en) * | 2011-10-06 | 2014-01-09 | The United States Government As Represented By The Department Of Veterans Affairs | Myosin binding protein-c for use in methods relating to diastolic heart failure |
| US11450431B2 (en) * | 2012-11-16 | 2022-09-20 | Siemens Healthcare Gmbh | Method to identify optimum coronary artery disease treatment |
| CA2953789A1 (en) | 2013-07-12 | 2015-01-15 | Emory University | Diagnostic assay to predict cardiovascular risk |
| TR201819992T4 (tr) | 2013-07-17 | 2019-02-21 | Abionic Sa | Bi̇yoassay i̇çi̇n yöntem ve ci̇haz |
| US20150160229A1 (en) * | 2013-12-06 | 2015-06-11 | Thomas D. Schaal | Methods for detection of heart failure |
| EP3140659A4 (en) * | 2014-05-08 | 2017-10-25 | University of Maryland, Baltimore | Methods for assessing differential risk for developing heart failure |
| PT3164213T (pt) | 2014-07-03 | 2024-03-25 | Abionic Sa | Cápsula para quantificação molecular rápida de uma amostra de fluido tal como sangue total |
| EP4574024A3 (en) | 2016-02-01 | 2025-10-08 | Prevencio, Inc. | Diagnostic and prognostic methods for cardiovascular diseases and events |
| JP7310591B2 (ja) | 2019-12-19 | 2023-07-19 | 株式会社オートネットワーク技術研究所 | 駆動装置 |
-
2017
- 2017-02-01 EP EP25170203.1A patent/EP4574024A3/en active Pending
- 2017-02-01 CN CN201780011650.8A patent/CN108700596A/zh active Pending
- 2017-02-01 BR BR112018015698A patent/BR112018015698A2/pt not_active Application Discontinuation
- 2017-02-01 MA MA043980A patent/MA43980A/fr unknown
- 2017-02-01 RU RU2018130866A patent/RU2018130866A/ru not_active Application Discontinuation
- 2017-02-01 MX MX2018009304A patent/MX2018009304A/es unknown
- 2017-02-01 SG SG11201805906WA patent/SG11201805906WA/en unknown
- 2017-02-01 AU AU2017214469A patent/AU2017214469A1/en not_active Abandoned
- 2017-02-01 WO PCT/US2017/016081 patent/WO2017136464A1/en not_active Ceased
- 2017-02-01 CN CN202210116587.7A patent/CN114441773A/zh active Pending
- 2017-02-01 EP EP17748086.0A patent/EP3411720B1/en active Active
- 2017-02-01 JP JP2018559674A patent/JP7134870B2/ja active Active
- 2017-02-01 US US16/073,754 patent/US10983135B2/en active Active
- 2017-02-01 KR KR1020187024496A patent/KR20180101595A/ko not_active Withdrawn
- 2017-02-01 CA CA3012192A patent/CA3012192A1/en active Pending
-
2020
- 2020-10-27 US US17/081,776 patent/US11977083B2/en active Active
-
2021
- 2021-06-10 JP JP2021097387A patent/JP7403498B2/ja active Active
-
2022
- 2022-09-21 JP JP2022150335A patent/JP2022171936A/ja active Pending
-
2023
- 2023-06-21 US US18/339,066 patent/US12146888B2/en active Active
-
2024
- 2024-10-11 US US18/913,852 patent/US20250060374A1/en active Pending
- 2024-12-09 JP JP2024214563A patent/JP2025029196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507354A5 (enExample) | ||
| Cheong et al. | Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction | |
| Sandoval et al. | Supply/demand type 2 myocardial infarction: should we be paying more attention? | |
| Rybicki et al. | 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS appropriate utilization of cardiovascular imaging in emergency department patients with chest pain: a joint document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force | |
| Patel et al. | Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice | |
| Tsang et al. | Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography | |
| Felker et al. | A standardized definition of ischemic cardiomyopathy for use in clinical research | |
| Brown et al. | Coarctation of the aorta: lifelong surveillance is mandatory following surgical repair | |
| Goonewardena et al. | Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure | |
| Lopez-Cuenca et al. | Comparison between type-2 and type-1 myocardial infarction: clinical features, treatment strategies and outcomes | |
| JP7762680B2 (ja) | 急性冠症候群のリスクを推定するための決定木ベースのシステム及び方法 | |
| Miller et al. | Stress CMR reduces revascularization, hospital readmission, and recurrent cardiac testing in intermediate-risk patients with acute chest pain | |
| RU2018130866A (ru) | Способы диагностики и прогнозирования сердечно-сосудистых заболеваний и явлений | |
| CN119199150A (zh) | 作为对象的细胞外容量状态的标志物的MR-proADM | |
| Chou et al. | Survival of older patients with advanced CKD managed without dialysis: a narrative review | |
| Kilinc et al. | Significance of serum cardiac troponin I levels in pulmonary embolism | |
| Carmelita et al. | Prevalence of renal artery stenosis in patients undergoing cardiac catheterization | |
| Niu et al. | Association of plasma B-type natriuretic peptide concentration with myocardial infarct size in patients with acute myocardial infarction | |
| Bayar et al. | Assessment of aortic elasticity in patients with celiac disease | |
| Attia et al. | Evaluation of acute pulmonary embolism by sixty-four slice multidetector CT angiography: Correlation between obstruction index, right ventricular dysfunction and clinical presentation | |
| Kwon et al. | Predictors of ischemic stroke for low-risk patients with atrial fibrillation: a matched case-control study | |
| Galeano-Valle et al. | Early surgical treatment in patients with pulmonary embolism and thrombus-in-transit | |
| Coyle et al. | Diagnostic testing in acute aortic dissection | |
| Hoshino et al. | Biomarkers of inflammation and fibrosis in young adults with history of Kawasaki disease | |
| Kong et al. | CTEPH: A Kaiser Permanente Northern California Experience |